NCT07431008 Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction
| NCT ID | NCT07431008 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pharmicell Co., Ltd. |
| Condition | Erectile Dysfunction |
| Study Type | OBSERVATIONAL |
| Enrollment | 32 participants |
| Start Date | 2024-12-26 |
| Primary Completion | 2030-01-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 32 participants in total. It began in 2024-12-26 with a primary completion date of 2030-01-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.
Eligibility Criteria
Inclusion Criteria: * Participants who previously participated in the parent clinical trial and received the cell therapy (Cellgram-ED). * Participants who have provided written informed consent to participate in this safety follow-up study. Exclusion Criteria:
Contact & Investigator
Bumjin Lim, Ph.D
PRINCIPAL INVESTIGATOR
AIDS Malignancy Consortium
Frequently Asked Questions
Who can join the NCT07431008 clinical trial?
This trial is open to male participants only, aged 19 Years or older, up to 80 Years, studying Erectile Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07431008 currently recruiting?
Yes, NCT07431008 is actively recruiting participants. Contact the research team at daeun4100@pharmicell.com for enrollment information.
Where is the NCT07431008 trial being conducted?
This trial is being conducted at Seoul, South Korea, Seoul, South Korea, Seoul, South Korea, Seoul, South Korea.
Who is sponsoring the NCT07431008 clinical trial?
NCT07431008 is sponsored by Pharmicell Co., Ltd.. The principal investigator is Bumjin Lim, Ph.D at AIDS Malignancy Consortium. The trial plans to enroll 32 participants.